Methods and compositions for eliciting an immune response against hepatitis B virus
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention relates to immunization of hypo-responsive groups of individuals. In particular, the present invention provides methods and compositions for eliciting a potent immune response to hepatitis B virus in individuals in need thereof.
Core Innovation
The invention describes HBV immunization using an immunogenic composition comprising hepatitis B surface antigen (HBsAg) and a CpG-containing immunostimulatory sequence (ISS), including a single-stranded 1018 ISS. The claimed approach concerns eliciting a seroprotective anti-HBsAg immune response in a human subject with chronic liver disease through an abbreviated vaccination schedule. [procedural detail omitted for safety]
The described results address immunization in hypo-responsive populations, including diabetic adults and people with chronic kidney disease. The document reports comparisons of seroprotection and antibody measures for HEPLISAV and ENGERIX-B in these and other populations, including adults aged 40 or older, males, obese subjects, and smokers. The background section is not included in the supplied content, so no further problem statement is available.
Claims Coverage
The supplied relevant claims identify one independent claim and one main inventive feature.
HBV immunization in a subject with chronic liver disease
A method for eliciting an immune response against hepatitis B virus (HBV) in a human subject with chronic liver disease, using an immunogenic composition comprising HBsAg and a single-stranded ISS, and eliciting a seroprotective immune response. [procedural detail omitted for safety]
The independent claim covers an HBsAg-and-ISS immunogenic composition for eliciting a seroprotective immune response against HBV in a human subject with chronic liver disease.
Stated Advantages
The document reports faster and higher seroprotection with HEPLISAV than with ENGERIX-B in diabetic and other hypo-responsive adults.
In chronic kidney disease populations, the document reports superior key antibody measures for HEPLISAV and similar overall safety profiles.
Documented Applications
Eliciting an immune response against HBV in a human subject with chronic liver disease.
HBV immunization in hypo-responsive populations described in the document, including adults with diabetes or chronic kidney disease, adults aged 40 or older, males, obese subjects, and smokers.
Interested in licensing this patent?